More Evidence for SGLT2 Inhibitors in Heart Failure

This editorial discusses the compelling and consistent evidence supporting the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure. It highlights that these benefits, particularly regarding a reduction in hospitalizations for heart failure, have been observed across different SGLT2 inhibitors and appear to be independent of the presence of diabetes. The editorial references landmark trials such as EMPA-REG OUTCOME, which demonstrated significant reductions in major adverse cardiovascular events, cardiovascular death, all-cause death, and progression of renal disease with empagliflozin, and the DAPA-HF trial, which further confirmed the positive effects of dapagliflozin in patients with heart failure and reduced ejection fraction. The author concludes that the consistent benefit regarding hospitalization for heart failure reinforces the importance of SGLT2 inhibitors in heart failure management.

This editorial discusses the compelling and consistent evidence supporting the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure. It highlights that these benefits, particularly regarding a reduction in hospitalizations for heart failure, have been observed across different SGLT2 inhibitors and appear to be independent of the presence of diabetes. The editorial references landmark trials such as EMPA-REG OUTCOME, which demonstrated significant reductions in major adverse cardiovascular events, cardiovascular death, all-cause death, and progression of renal disease with empagliflozin, and the DAPA-HF trial, which further confirmed the positive effects of dapagliflozin in patients with heart failure and reduced ejection fraction. The author concludes that the consistent benefit regarding hospitalization for heart failure reinforces the importance of SGLT2 inhibitors in heart failure management.